IDEAYA Biosciences 관리

관리 기준 확인 2/4

IDEAYA Biosciences CEO는 Yujiro Hata, Jun2015 에 임명되었습니다 의 임기는 9.5 년입니다. 총 연간 보상은 $ 6.00M, 10% 로 구성됩니다. 10% 급여 및 90% 보너스(회사 주식 및 옵션 포함). 는 € 16.64M 가치에 해당하는 회사 주식의 0.78% 직접 소유합니다. 16.64M. 경영진과 이사회의 평균 재임 기간은 각각 2 년과 6.1 년입니다.

주요 정보

Yujiro Hata

최고 경영자

US$6.0m

총 보상

CEO 급여 비율	10.0%
CEO 임기	9.5yrs
CEO 소유권	0.8%
경영진 평균 재임 기간	2yrs
이사회 평균 재임 기간	6.1yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Yujiro Hata 의 보수는 IDEAYA Biosciences 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$178m
Jun 30 2024	n/a	n/a	-US$154m
Mar 31 2024	n/a	n/a	-US$129m
Dec 31 2023	US$6m	US$598k	-US$113m
Sep 30 2023	n/a	n/a	-US$103m
Jun 30 2023	n/a	n/a	-US$74m
Mar 31 2023	n/a	n/a	-US$68m
Dec 31 2022	US$3m	US$570k	-US$59m
Sep 30 2022	n/a	n/a	-US$53m
Jun 30 2022	n/a	n/a	-US$66m
Mar 31 2022	n/a	n/a	-US$55m
Dec 31 2021	US$4m	US$544k	-US$50m
Sep 30 2021	n/a	n/a	-US$37m
Jun 30 2021	n/a	n/a	-US$30m
Mar 31 2021	n/a	n/a	-US$31m
Dec 31 2020	US$2m	US$510k	-US$34m
Sep 30 2020	n/a	n/a	-US$40m
Jun 30 2020	n/a	n/a	-US$46m
Mar 31 2020	n/a	n/a	-US$44m
Dec 31 2019	US$2m	US$457k	-US$42m
Sep 30 2019	n/a	n/a	-US$40m
Jun 30 2019	n/a	n/a	-US$42m
Mar 31 2019	n/a	n/a	-US$38m
Dec 31 2018	US$2m	US$420k	-US$34m

보상 대 시장: Yujiro 의 총 보상 ($USD 6.00M )은 German 시장( $USD 1.58M ).

보상과 수익: 회사가 수익성이 없는 동안 Yujiro 의 보상이 증가했습니다.

CEO

Yujiro Hata (50 yo)

9.5yrs

테뉴어

US$5,995,440

보상

Mr. Yujiro S. Hata is Director since November 2024 at Hexagon Bio, Inc. He serves as an Independent Director at Enanta Pharmaceuticals, Inc. since August 29, 2021. He is a Co-Founder of IDEAYA Biosciences,...

리더십 팀

이름	위치	테뉴어	보상	소유권
Yujiro Hata	President	9.5yrs	US$6.00m	0.78% € 16.6m
Andres Briseno	Principal Accounting Officer	3.9yrs	US$1.41m	0.028% € 602.1k
Michael White	Chief Scientific Officer	3.1yrs	US$2.76m	데이터 없음
Darrin Beaupre	Chief Medical Officer	2.1yrs	US$1.81m	0% € 0
Paul Barsanti	Chief Technology Officer	1.9yrs	데이터 없음	데이터 없음
Douglas Snyder	Senior VP & General Counsel	less than a year	데이터 없음	데이터 없음
Francine Zelaya	Vice President & Head of Human Resources	less than a year	데이터 없음	데이터 없음
Mick O'Quigley	Chief of Staff & Clinical Development	2.8yrs	데이터 없음	데이터 없음
Daniel Simon	Chief Business Officer	less than a year	데이터 없음	데이터 없음
Stuart Dorman	Chief Commercial Officer	no data	데이터 없음	데이터 없음

2.0yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 관리: 30J 의 관리팀은 경험 ( 2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Yujiro Hata	President	9.5yrs	US$6.00m	0.78% € 16.6m
Wendy Yarno	Independent Director	5yrs	US$358.02k	0% € 0
Jeffrey Stein	Independent Director	9.2yrs	US$363.02k	0.0050% € 105.0k
Susan Kelley	Independent Director	3.8yrs	US$349.52k	0% € 0
Frank McCormick	Chair of Scientific Advisory Board	5.8yrs	데이터 없음	데이터 없음
Scott William Morrison	Independent Director	6.4yrs	US$364.52k	0% € 0
Catherine Mackey	Independent Director	2.7yrs	US$350.52k	0% € 0
Trey Ideker	Member of Scientific Advisory Board	8.6yrs	데이터 없음	데이터 없음
William Sellers	Member of Scientific Advisory Board	5.8yrs	데이터 없음	데이터 없음
Elizabeth Swisher	Member of Scientific Advisory Board	8.6yrs	데이터 없음	데이터 없음
Terry Rosen	Independent Chairman of the Board	8.9yrs	US$369.52k	0.019% € 401.2k
Malcolm Hampton	Independent Director	4.5yrs	US$349.52k	0% € 0

6.1yrs

평균 재임 기간

67.5yo

평균 연령

경험이 풍부한 이사회: 30J 의 이사회는 경험(평균 재직 기간 6.1 년)으로 간주됩니다.

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/23 12:12
장 마감 주가	2024/12/20 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

IDEAYA Biosciences, Inc. 25 애널리스트 중 14 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Madhu Kumar	Baird
Zhiqiang Shu	Berenberg
Justin Zelin	BTIG

IDEAYA Biosciences 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

IDEAYA Biosciences, Inc. Appoints Stu Dorman as Chief Commercial Officer

IDEAYA Biosciences, Inc. Appoints Douglas B. Snyder as Senior Vice President, General Counsel

IDEAYA Biosciences, Inc Announces Resignation of Jason Throne as Chief Legal Officer and Secretary, Effective July 11, 2024

IDEAYA Biosciences, Inc. Appoints Daniel A. Simon as Chief Business Officer, Effective August 2024

IDEAYA Biosciences, Inc., Annual General Meeting, May 31, 2024

IDEAYA Biosciences, Inc. Announces Resignation of Paul A. Stone as Chief Financial Officer

Recent updates

IDEAYA Biosciences, Inc. Announces IDMCRecommendation of Move-Forward Dose in Part 2A of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma

Ideaya Biosciences, Inc. Announces First-Patient-In for Phase 1 Clinical Trial Evaluating Ide161 in Combination with Keytruda®? (Pembrolizumab) in Patients with Endometrial Cancer

IDEAYA Biosciences, Inc. Appoints Stu Dorman as Chief Commercial Officer

New minor risk - Revenue size

IDEAYA Biosciences, Inc. Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors

IDEAYA Biosciences, Inc. Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024

IDEAYA Biosciences, Inc. Appoints Douglas B. Snyder as Senior Vice President, General Counsel

First half 2024 earnings released: US$1.21 loss per share (vs US$0.98 loss in 1H 2023)

IDEAYA Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $263.000016 million.

IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) dropped from Russell 3000E Value Index

IDEAYA Biosciences, Inc Announces Resignation of Jason Throne as Chief Legal Officer and Secretary, Effective July 11, 2024

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy Combination in MTAP-Deletion Bladder Cancer

IDEAYA Biosciences, Inc. Announces Clinical Program Updates for Ide397 A Potential First-In-Class Phase 2 Mat2a Inhibitor Targeting MTAP-Deletion Solid Tumors

IDEAYA Biosciences, Inc. Announces Results for darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma At Asco and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study

IDEAYA Biosciences, Inc. Appoints Daniel A. Simon as Chief Business Officer, Effective August 2024

First quarter 2024 earnings released: US$0.53 loss per share (vs US$0.49 loss in 1Q 2023)

IDEAYA Biosciences, Inc., Annual General Meeting, May 31, 2024

IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer

Full year 2023 earnings released: US$1.96 loss per share (vs US$1.42 loss in FY 2022)

New major risk - Shareholder dilution

IDEAYA Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $350 million.

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.46 loss per share (vs US$0.04 profit in 3Q 2022)

IDEAYA Announces Top-Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ/11 Cutaneous Melanoma, and Synthetic Lethality Pipeline

New minor risk - Share price stability

IDEAYA Biosciences, Inc. Announces Resignation of Paul A. Stone as Chief Financial Officer

IDEAYA Biosciences, Inc. Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in (Neo) Adjuvant Uveal Melanoma

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.50 loss per share (vs US$0.57 loss in 2Q 2022)

IDEAYA Biosciences, Inc. Appoints Andres Ruiz Briseno as Principal Accounting Officer

New major risk - Shareholder dilution

IDEAYA Announces Selection of IDE397 Phase 2 Monotherapy Expansion Dose For Global Enrollment Targeting High Priority MTAP-Deletion Solid Tumor Types

First quarter 2023 earnings released: US$0.49 loss per share (vs US$0.36 loss in 1Q 2022)

Full year 2022 earnings released: US$1.42 loss per share (vs US$1.41 loss in FY 2021)

IDEAYA Biosciences, Inc. Announces Darovasertib Phase 2 Initiation in Neoadjuvant and Adjuvant Uveal Melanoma and Guidance for Clinical Data Update in Metastatic Uveal Melanoma

IDEAYA Biosciences, Inc. Announces Board Appointments

IDEAYA Biosciences, Inc Announces Submission of IND Application to the U.S. FDA for PARG Development Candidate IDE161

IDEAYA Biosciences, Inc. Appoints Darrin M. Beaupre as Chief Medical Officer to Lead Clinical Development of Expanding Clinical Pipeline

Third quarter 2022 earnings released: EPS: US$0.04 (vs US$0.31 loss in 3Q 2021)

IDEAYA Biosciences, Inc. Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First-Patient-In for Multiple Combination Cohorts in MTAP-Deletion Tumors

IDEAYA Biosciences, Inc. Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination in Metastatic Uveal Melanoma

IDEAYA Biosciences, Inc. Announces First-Patient-In for Phase I Clinical Trial to Evaluate Darovasertib Monotherapy in (Neo)Adjuvant Uveal Melanoma

IDEAYA Announces Achievement of First Milestone in Ongoing Collaboration with GSK for Potential First-In-Class Pol Theta Helicase Inhibitor Development Candidate

Second quarter 2022 earnings released: US$0.57 loss per share (vs US$0.33 loss in 2Q 2021)

IDEAYA Biosciences, Inc. Announces Clinical Trial Collaboration with Amgen to Evaluate MAT2A-PRMT5 Synthetic Lethality Combination in MTAP Deleted Tumors

IDEAYA Biosciences, Inc. Announces Development Candidate Nomination of Potential First-In-Class Pol Theta Helicase Inhibitor in Collaboration with GSK

IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) dropped from Russell 2000 Growth Index

IDEAYA Biosciences, Inc. Appoints Catherine Mackey to its Board of Directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

IDEAYA Biosciences, Inc. Advances First-in-Class PARG Development Candidate, IDE161, into IND-Enabling Studies and Exercises Option with Cancer Research UK and University of Manchester for Exclusive Worldwide License

IDEAYA Biosciences, Inc. Reports Clinical Data from Phase 2 Expansion Dose of Darovasertib and Crizotinib Synthetic Lethal Combination in Heavily Pre-Treated Metastatic Uveal Melanoma

Director Yujiro Hata has joined 3rd company board

IDEAYA Announces Dose Expansion in Phase 1/2 Study of Darovasertib and Crizotinib Combination based on Early Clinical Efficacy in First Combination Cohort

New 90-day high: €17.80

IDEAYA Biosciences, Inc. Appoints Susan L. Kelley to its Board of Directors

New 90-day high: €16.40

IDEAYA Biosciences, Inc. Announces Appointment of Matthew Maurer as Head of Clinical Oncology and Medical Affairs

New 90-day high: €16.30

Spelman College and IDEAYA Biosciences Announce Partnership for Professional Development of the Next Generation of Female African American Leaders in the Biotechnology Industry

IDEAYA Biosciences, Inc. Announces Submission of IND Application for MAT2A Development Candidate IDE397 with the U.S. FDA

IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Crizotinib, a cMET Inhibitor

New 90-day low: €10.10

Nasdaq Biotechnology Index Selects IDEAYA Biosciences, Inc

New 90-day high: €12.70

IDEAYA Biosciences, Inc. and Pfizer Inc. Expand Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Crizotinib in Solid Tumors Harboring GNAQ or GNA11 Mutations

IDEAYA Biosciences, Inc. Names Garret Hampton to the Nominating and Corporate Governance Committee

IDEAYA Biosciences, Inc. announced that it has received $19.999995 million in funding from Glaxosmithkline Intellectual Property (No.4) Limited

CEO 보상 분석

CEO